Nectin-4/PVRL4 has also been proposed as a therapeutic target of primary and metastatic triple-negative breast cancers, as well as of lung, bladder, and pancreatic cancers which could potentially be treated with Nectin-4/PVRL4 antibodies conjugated to anti-neoplastic agents57,58. This evidence concerns the gene NECTIN4 and triple-negative breast carcinoma.